This article was originally published in The Gray Sheet
Executive SummaryTwo firms sign a definitive agreement for EG&G to acquire Wallac, a unit of Procordia AB, for approximately $46 mil. Headquartered in Finland and with employees in Scandinavia, the U.K. and the U.S., Wallac posted roughly $50 mil. in 1992 sales. The producer of analytical and diagnostic systems, instruments and reagents will report to EG&G's instruments division, which markets medical, environmental and analytic monitoring products and accounts for approximately $227 mil. of EG&G's $2.7 bil. in annual revenues.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.